CJC-1295 NO DAC 5 mg

CJC-1295 no DAC 5 mg reagent - characteristics

CJC-1295 no DAC 5 mg is a synthetic research peptide included in the group of short-acting growth hormone-releasing hormone analogues (GHRH / GRF). In research practice and market nomenclature, this variant is sometimes referred to modified analogues of GRF(1-29) devoid of component DAC (Drug Affinity Complex), and therefore to designed forms without a mechanism for permanent binding to albumin. For this reason CJC-1295 no DAC 5 mg is described as a peptide with a shorter duration of action than the variant with DAC, analysed primarily in the context of more physiological, shorter axis stimulation GH/IGF-1.

In the scientific literature, short-acting analogues of GRF(1-29), with which it is identified in practice CJC-1295 no DAC 5 mg, are primarily described in terms of mechanisms related to receptor activation GHRH on somatotropic cells of the pituitary gland and secondary stimulation of the secretion of GH. The key research importance of this group of peptides stems from attempts to preserve the biological activity of natural GRF(1-29) while increasing metabolic stability through amino acid substitutions, but without imparting to the molecule the prolonged, albumin-dependent action characteristic of the form of the DAC.

The pharmacokinetic and functional difference between the CJC-1295 with DAC and the option no DAC. Data on the form with DAC show a markedly prolonged half-life, reaching several days due to persistent binding to albumin, while the non-DAC variant is described as shorter-acting and closer to classical pulsatile analogues GHRH. It is the absence of an albumin-binding component that is the main distinguishing feature of the CJC-1295 no DAC 5 mg and causes it to be positioned differently in laboratory analyses than the long-acting form.

See also peptide reagent CJC-1295 DAC 5 mg

From a scientific characterisation perspective, the following are among the main research strengths CJC-1295 no DAC 5 mg includes its link to the well-described biology of the pathway GHRH, the small particle size and the possibility to analyse shorter, more transient stimulation of the axis GH/IGF-1 than the DAC form. At the same time, it is important to emphasise that much of the hard clinical and pharmacokinetic data primarily relate to the CJC-1295 with DAC, while the option no DAC is sometimes described more in the technical circuit and in research practice than in the equally extensive clinical literature. Interpretation of the results should therefore take into account both the inconsistency of the nomenclature and the limited number of direct publications on this particular form.

Scientific and technical sources:

1. Work on the identification of CJC-1295 as a stable analogue of hGRF(1-29) with substitutions to enhance activity and stability.
2. Clinical study showing that CJC-1295 with DAC prolongs GH/IGF-1 stimulation through a mechanism of binding to albumin.
3. A 2024 FDA document highlighting that the CJC-1295 i CJC-1295 DAC are different active moiety and are not interchangeable.
4. Technical sources describing the use of the name CJC-1295 without DAC / Mod GRF(1-29) for a short-acting variant without the DAC complex.

The product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.